Drug Profile
Research programme: antiviral and anticancer ribonucleases - Tamir Biotechnology
Alternative Names: AC CJ-001; AC-03-636; Amphinase 3; Natural P31 - Tamir; rAmphinase 2 - Tamir; Recombinant amphinase 2 - Tamir; TMR-004Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Alfacell Corporation
- Developer Johns Hopkins University; National Institute of Allergy and Infectious Diseases; Tamir Biotechnology; United States Army Medical Research Institute of Infectious Diseases
- Class Ribonucleases
- Mechanism of Action Mitosis inhibitors; Ribonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain cancer; Cytomegalovirus infections; Dengue; Ebola virus infections; Human papillomavirus infections; Severe acute respiratory syndrome; Yellow fever
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Intraperitoneal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)